TW202135815A - 醫藥組合物 - Google Patents

醫藥組合物 Download PDF

Info

Publication number
TW202135815A
TW202135815A TW109143111A TW109143111A TW202135815A TW 202135815 A TW202135815 A TW 202135815A TW 109143111 A TW109143111 A TW 109143111A TW 109143111 A TW109143111 A TW 109143111A TW 202135815 A TW202135815 A TW 202135815A
Authority
TW
Taiwan
Prior art keywords
pharmaceutical composition
poloxamer
suspension
alkyl
polyethylene glycol
Prior art date
Application number
TW109143111A
Other languages
English (en)
Chinese (zh)
Inventor
尼瑪 艾克哈文
凱文 邱
埃米爾 斐堤森
Original Assignee
美商 Ｖｉｉｖ 醫療保健公司
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 美商 Ｖｉｉｖ 醫療保健公司 filed Critical 美商 Ｖｉｉｖ 醫療保健公司
Publication of TW202135815A publication Critical patent/TW202135815A/zh

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/4985—Pyrazines or piperazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/541—Non-condensed thiazines containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A61K31/765—Polymers containing oxygen
    • A61K31/77—Polymers containing oxygen of oxiranes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • AIDS & HIV (AREA)
  • Dermatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
TW109143111A 2019-12-09 2020-12-07 醫藥組合物 TW202135815A (zh)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201962945412P 2019-12-09 2019-12-09
US62/945,412 2019-12-09
US202062982305P 2020-02-27 2020-02-27
US62/982,305 2020-02-27

Publications (1)

Publication Number Publication Date
TW202135815A true TW202135815A (zh) 2021-10-01

Family

ID=73834567

Family Applications (1)

Application Number Title Priority Date Filing Date
TW109143111A TW202135815A (zh) 2019-12-09 2020-12-07 醫藥組合物

Country Status (14)

Country Link
US (1) US20230045509A1 (https=)
EP (1) EP4072520B1 (https=)
JP (1) JP7703538B2 (https=)
KR (1) KR20220112771A (https=)
CN (1) CN114786648A (https=)
AU (1) AU2020402659A1 (https=)
BR (1) BR112022010574A2 (https=)
CA (1) CA3164528A1 (https=)
ES (1) ES3051362T3 (https=)
IL (1) IL293566A (https=)
MX (1) MX2022006940A (https=)
TW (1) TW202135815A (https=)
UY (1) UY38982A (https=)
WO (1) WO2021116872A1 (https=)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202128648A (zh) * 2019-10-04 2021-08-01 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
US20220370451A1 (en) * 2019-10-08 2022-11-24 VIIV HEALTHCARE UK ( No. 5) LIMITED Inhibitors of human immunodeficiency virus replication
KR20220151655A (ko) * 2020-03-06 2022-11-15 비브 헬스케어 유케이 (넘버5) 리미티드 인간 면역결핍 바이러스 복제의 억제제
WO2021188959A1 (en) * 2020-03-20 2021-09-23 Gilead Sciences, Inc. Prodrugs of 4'-c-substituted-2-halo-2'-deoxyadenosine nucleosides and methods of making and using the same
BR112022020933A2 (pt) * 2020-04-15 2022-12-06 Viiv Healthcare Uk No 5 Ltd Inibidores de replicação do vírus da imunodeficiência humana
WO2022051198A1 (en) 2020-09-01 2022-03-10 Viiv Healthcare Company Combination of cabotegravir and levonorgestrel
JP2024500322A (ja) * 2020-12-07 2024-01-09 ヴィーブ、ヘルスケア、カンパニー 併用療法
KR20240122840A (ko) * 2021-12-17 2024-08-13 비이브 헬쓰케어 컴퍼니 Hiv 감염에 대한 조합 요법 및 그의 용도
US20250042926A1 (en) 2023-05-31 2025-02-06 Gilead Sciences, Inc. Therapeutic compounds for hiv
AU2024353051A1 (en) 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical compositions
AU2023466962A1 (en) * 2023-09-27 2026-03-12 ViiV Healthcare UK (No.3) Limited Pharmaceutical composition of cabotegravir
WO2025128498A1 (en) * 2023-12-12 2025-06-19 Viiv Healthcare Company Pharmaceutical compositions
TW202547514A (zh) 2024-02-05 2025-12-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 5)有限公司 人類免疫不全病毒複製之抑制劑
TW202602442A (zh) 2024-03-01 2026-01-16 英商Ｖｉｉｖ醫療保健英國(Ｎｏ 3)有限公司 給藥方案

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7550155B2 (en) * 2002-07-29 2009-06-23 Transform Pharmaceuticals Inc. Aqueous pharmaceutical compositions of 2,6-diisopropylphenol (propofol) and their uses
KR101363875B1 (ko) 2005-04-28 2014-02-21 시오노기세야쿠 가부시키가이샤 Ｈｉｖ 통합효소 억제 활성을 가지는 다환식카르바모일피리돈 유도체
TWI577377B (zh) * 2010-09-16 2017-04-11 Ｖｉｉｖ醫療保健公司 醫藥組合物
WO2015127437A1 (en) * 2014-02-24 2015-08-27 The Board Of Regents Of The University Of Nebraska Compositions and methods for the delivery of therapeutics
WO2015143712A1 (en) * 2014-03-28 2015-10-01 Merck Sharp & Dohme Corp. 4'-substituted nucleoside reverse transcriptase inhibitors
UY36070A (es) * 2014-04-11 2015-10-30 Bristol Myers Squibb Company Una Corporación Del Estado De Delaware Triterpenoides con actividad inhibidora de la maduración de hiv
EP3197430A1 (en) * 2014-09-26 2017-08-02 Glaxosmithkline Intellectual Property (No. 2) Limited Long acting pharmaceutical compositions
AR107512A1 (es) 2016-02-04 2018-05-09 VIIV HEALTHCARE UK Nº 5 LTD Triterpenoides modificados en c-3 y c-17 como inhibidores del vih-1
US20170232020A1 (en) * 2016-02-12 2017-08-17 Cipla Limited Pharmaceutical compositions
US11117904B2 (en) * 2016-06-23 2021-09-14 Viiv Healthcare Company Compositions and methods for the delivery of therapeutics
EP3478324A1 (en) * 2016-07-01 2019-05-08 GlaxoSmithKline Intellectual Property (No.2) Limited Antibody-drug conjugates and therapeutic methods using the same
TW201906834A (zh) * 2017-05-02 2019-02-16 英商Viiv醫療保健英國(No.5)有限公司 人類免疫不全病毒複製之抑制劑
EP3762396A1 (en) * 2018-03-07 2021-01-13 GlaxoSmithKline Intellectual Property (No.2) Limited Compounds useful in hiv therapy
EP3774775B8 (en) * 2018-04-11 2023-11-15 VIIV Healthcare UK (No.5) Limited 4-oxo-3,4-dihydroquinazoline compounds as inhibitors of human immunodeficiency virus replication
ES2970042T3 (es) * 2018-04-24 2024-05-24 Viiv Healthcare Uk No 5 Ltd Compuestos con actividad inhibidora de la maduración del VIH
KR20210033492A (ko) * 2018-07-16 2021-03-26 길리애드 사이언시즈, 인코포레이티드 Hiv의 치료를 위한 캡시드 억제제
US11541055B2 (en) 2018-10-24 2023-01-03 VIIV Healthcare UK (No.5) Limited Inhibitors of human immunodeficiency virus replication
CN120535538A (zh) * 2018-11-29 2025-08-26 内布拉斯加大学董事会 抗病毒前药及其纳米制剂
UY38559A (es) * 2019-02-01 2020-07-31 Viiv Healthcare Uk No 5 Ltd Inhibidores de la replicación del virus de la inmunodeficiencia humana
CN113811360A (zh) 2019-03-06 2021-12-17 葛兰素史密斯克莱知识产权（第2 号）有限公司 用于hiv治疗的化合物
US20220211704A1 (en) * 2019-04-30 2022-07-07 Viiv Healthcare Uk (No. 5) Limited Inhibitors of human immunodeficiency virus replication
BR112021025655A2 (pt) * 2019-06-19 2022-02-01 Viiv Healthcare Uk No 5 Ltd Inibidores da replicação do vírus da imunodeficiência humana
KR20220066303A (ko) * 2019-09-11 2022-05-24 더 스크립스 리서치 인스티튜트 항바이러스 전구약물 및 이의 약제학적 조성물

Also Published As

Publication number Publication date
IL293566A (en) 2022-08-01
MX2022006940A (es) 2022-07-11
AU2020402659A1 (en) 2022-06-02
KR20220112771A (ko) 2022-08-11
EP4072520A1 (en) 2022-10-19
EP4072520C0 (en) 2025-09-24
CA3164528A1 (en) 2021-06-17
WO2021116872A1 (en) 2021-06-17
US20230045509A1 (en) 2023-02-09
EP4072520B1 (en) 2025-09-24
JP2023505543A (ja) 2023-02-09
JP7703538B2 (ja) 2025-07-07
UY38982A (es) 2021-06-30
BR112022010574A2 (pt) 2022-08-23
ES3051362T3 (en) 2025-12-26
CN114786648A (zh) 2022-07-22

Similar Documents

Publication Publication Date Title
TW202135815A (zh) 醫藥組合物
ES2369893T3 (es) Suspensión inyectable de aripiprazol.
TWI738632B (zh) 穩定的含有高濃度抗vegf抗體之蛋白質溶液調配物
JP2022105625A (ja) 高濃度抗ｃ５抗体製剤
ES2902325T3 (es) Composición farmacéutica oftálmica
US20240182554A1 (en) Protein solution formulation containing high concentration of an anti-vegf antibody
KR20180118136A (ko) Nk-1 수용체 길항제를 포함하는 에멀젼
JP2017528497A (ja) 長時間作用型医薬組成物
US20260021091A1 (en) Pharmaceutical compositions
US20230321089A1 (en) Combination of cabotegravir and levonorgestrel
AU2023466962A1 (en) Pharmaceutical composition of cabotegravir
US20190231688A1 (en) Method of administering emulsion formulations of an nk-1 receptor antagonist
TW201130826A (en) Ophthalmic formulations containing substituted gamma lactams and methods for use thereof
TW202602442A (zh) 給藥方案
TW202543637A (zh) 醫藥組合物
JP2020525054A (ja) モキシフロキサシンを含有するプレフィルドシリンジ
EA045866B1 (ru) Состав терапевтического антитела
WO2026078715A1 (en) Injectable composition of aprepitant
IL324204A (en) Long-acting colloidal pharmaceutical compositions of integrase strand transfer inhibitors and related methods